KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Cash from Financing Activities (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Cash from Financing Activities for 9 consecutive years, with -$218.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 5320.54% year-over-year to -$218.0 million, compared with a TTM value of -$349.9 million through Dec 2025, down 5974.14%, and an annual FY2025 reading of -$349.9 million, down 5974.14% over the prior year.
  • Cash from Financing Activities was -$218.0 million for Q4 2025 at Biocryst Pharmaceuticals, down from -$58.8 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $29.4 million in Q2 2023 and bottomed at -$218.0 million in Q4 2025.
  • Average Cash from Financing Activities over 3 years is -$26.9 million, with a median of -$1.5 million recorded in 2024.
  • Peak annual rise in Cash from Financing Activities hit 150.48% in 2025, while the deepest fall reached 5320.54% in 2025.
  • Year by year, Cash from Financing Activities stood at -$3.2 million in 2023, then decreased by 26.73% to -$4.0 million in 2024, then plummeted by 5320.54% to -$218.0 million in 2025.
  • Business Quant data shows Cash from Financing Activities for BCRX at -$218.0 million in Q4 2025, -$58.8 million in Q3 2025, and -$73.7 million in Q2 2025.